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ABSTRACT: The ﬁrst enantioselective total synthesis of the
epipolythiodiketopiperazine (ETP) natural product (−)-acety-
lapoaranotin (3) is reported. The concise synthesis was enabled
by an eight-step synthesis of a key cyclohexadienol-containing
amino ester building block. The absolute stereochemistry of
both amino ester building blocks used in the synthesis is set
through catalytic asymmetric (1,3)-dipolar cycloaddition reactions. The formal syntheses of (−)-emethallicin E and
(−)-haemotocin are also achieved through the preparation of a symmetric cyclohexadienol-containing diketopiperazine.
The epipolythiodiketopiperazine (ETP) fungal metabolitesare fascinating natural products in terms of both their
structural features and biological properties.1 Although they are
biosynthetically2 related to diketopiperazines (DKPs)a
widespread and structurally diverse family of natural products
produced by plants, bacteria, and fungi3ETPs are exclusively
isolated from fungal species. In many cases, they are
hypothesized to serve as virulence or defense factors and
exhibit various antimicrobial, antiviral, and anticancer activities.1
The disulﬁde is the key structural feature that confers
bioactivity; although many of the corresponding S-methylated
compounds have been isolated, these compounds typically have
greatly reduced cytotoxicities.4
Given their interesting structures and biological activities, the
ETPs have attracted considerable interest from synthetic
chemists (see Figure 1 for representative structures).5 Pioneer-
ing synthetic studies were conducted by Kishi and co-workers,
resulting in the ﬁrst total synthesis of gliotoxin (2) in 1976.6,7
More recently, Nicolaou and colleagues reported a general
approach to the cyclohexadienol-containing ETPs, resulting in
the syntheses of gliotoxin (2), emethallicin E (4), and several
other structurally related natural and non-natural ETPs from
commercially available L-N-Boc-tyrosine.8 Our laboratory
published the ﬁrst total synthesis of a dihydrooxepine-
containing ETP, acetylaranotin (1),9,10 which was followed
closely by a synthesis from Tokuyama and co-workers.11 In
addition, a number of elegant syntheses of pyrroloindoline-
containing ETPs have been reported.12
As part of our eﬀorts to develop a uniﬁed strategy to prepare
members of both the dihydrooxepine-containing and cyclo-
hexadienol-containing ETPs, we became interested in acetyla-
poaranotin (3), the heterodimeric natural product that links
these two subfamilies. 3 was ﬁrst reported by Neuss and co-
workers as part of their studies characterizing the structure and
biological activities of metabolites produced by the fungus
Arachniotus aureus.5h Decades later, Yang and co-workers
isolated 3 from Aspergillus sp. KMD 901 and determined that
it induces apoptosis in HCT116 colon cancer cells.13 Here, we
report the ﬁrst total synthesis of 3, which was enabled by an
eight-step, enantioselective synthesis of a key amino acid
building block, 7.
Retrosynthetically, our approach to 3 called for DKP
formation and sulfenylation as the ﬁnal steps of the synthesis,
thus reducing the synthetic challenge to the preparation of the
corresponding amino acid building blocks 6 and 7, the former
of which we had previously prepared during our synthesis of
(−)-acetylaranotin (1) (Figure 1).9 The silyl-protected cyclo-
hexadienol 7 was envisioned to arise from siloxyenone 8, which
we expected to be available in short order from pyrrolidine 9. In
analogy to our synthesis of 1, 9 would be prepared from the
product of a Cu-catalyzed asymmetric (1,3)-dipolar cyclo-
addition14 using simple starting materials: acrylamide 10,
cinnamaldehyde (12), and ethyl glycinate (11). Moreover, in
the long term, we anticipate that intermediates 7 and 8 could
enable the synthesis of additional ETPs, including epicorazine
A (5, Figure 1).5j
Our studies began with the synthesis of cyclohexadienol 7
(Scheme 1). To this end, Cu(I)/brucin-OL-catalyzed14 (1,3)-
dipolar cycloaddition between Weinreb amide 10 and the imine
derived from cinnamaldehyde (12) and ethyl glycinate (11)
provided pyrrolidine 13 in 42% yield and 95% enantiomeric
excess (ee) on 15 mmol scale. The modest yields result in part
from the propensity of pyrrolidine 13 to engage in a second
(1,3)-dipolar cycloaddition to give the corresponding pyrroli-
zidine.15 Although the yield for this transformation was slightly
lower than that obtained using tert-butyl acrylate (as in our
synthesis of acetylaranotin9), it was advantageous to obtain
Weinreb amide 13 directly from the dipolar cycloaddition and
avoid subsequent functional group interconversions. Following
protection of pyrrolidine 13 as the 2-(trimethylsilyl)ethyl
carbamate (Teoc, 14), we sought to execute a chemoselective
Received: February 17, 2017
Published: March 28, 2017
Letter
pubs.acs.org/OrgLett
© 2017 American Chemical Society 1698 DOI: 10.1021/acs.orglett.7b00418
Org. Lett. 2017, 19, 1698−1701
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
1,2-addition of allyl magnesium chloride to the Weinreb amide.
As expected, this transformation proved challenging due to
competing addition of the organometallic reagent to the ethyl
ester. Nevertheless, by carefully controlling the equivalents of
the Grignard reagent and maintaining cold temperatures
through dropwise addition, allyl ketone 9 could be isolated in
51% yield on a multigram scale.
Exposure of diene 9 to the second generation Hoveyda−
Grubbs catalyst (HG-II)16 yielded ring-closing metathesis
product 15 in good yield (Scheme 1). β,γ-Unsaturated enone
15 was immediately treated with dimethyldioxirane (DMDO)
to provide the epoxide, which was subsequently heated in a
toluene slurry of silica gel to aﬀord γ-hydroxy enone 16 as an
inseparable 6.5:1 mixture of diastereomers. Following protec-
tion of alcohols 16 as the TBS ethers, the diastereomers could
be separated using silica gel chromatography to furnish 8 in
72% isolated yield. Conversion of 8 to the enol triﬂate was
followed by palladium-catalyzed reduction11a to arrive at TBS-
protected cyclohexadienol 7 in 8 steps from ethyl glycinate.
At this stage, a sequential peptide coupling was employed to
prepare the diketopiperazine (Scheme 2). Thus, saponiﬁcation
of the ethyl ester of 7 with trimethyltinhydroxide aﬀorded
carboxylic acid 17.17 Amide coupling between acid 17 and
dihydrooxepine-containing amine 18 was achieved in high yield
using BOP-Cl. Treatment of dipeptide 19 with TBAF·
(tBuOH)4 in acetonitrile at 60 °Cthe conditions developed
for global desilylation and DKP formation in our synthesis of
acetylaranotin9led to elimination of the dienyl alcohol to give
the corresponding arene.18 This undesired reactivity could be
Figure 1. Representative ETP natural products and retrosynthetic
analysis.
Scheme 1. Enantioselective Synthesis of 7
Scheme 2. Completion of the Synthesis of
(−)-Acetylapoaranotin (3)
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mitigated when the reaction was conducted with excess TBAF
at room temperature, providing diol 20 in 47% yield. In
addition to removal of the three silyl protecting groups with
concomitant DKP formation, these conditions result in
epimerization to give the thermodynamically preferred anti-
syn-anti diastereomer (stereochemistry highlighted in red) of
the central diketopiperazine. The somewhat moderate yield
results from an inability to completely prevent the formation of
arene side products under basic conditions; the corresponding
syn-syn-syn diastereomer was not detected.
Given the sensitivity of diol 20 to base, it was unsurprising
that the subsequent sulfenylation proved challenging. Ulti-
mately, tetrasulﬁde 21 could be isolated in 23% yield using the
protocol developed by Nicolaou et al.,8a which employs
LiHMDS as the base; indole 22 was also obtained in 18%
yield. Use of NaHMDS instead of LiHMDS provided
substantially lower yields. Tetrasulﬁde 21 was converted to
the natural product, 3, by diacetylation, reduction to the dithiol,
and aerobic oxidation to the disulﬁde. This represents the ﬁrst
synthesis of acetylapoaranotin, which proceeds in 18 steps
(longest linear sequence) from ethyl glycinate.19 The
propensity to form indole 22 highlights a unique challenge
presented by heterodimeric ETP 3: the cyclohexadienol
fragment is sensitive to base, while the dihydrooxepine moiety
is unstable to acid, therefore strictly limiting the tactics suitable
for disulﬁde formation.
In addition to preparing acetylapoaranotin, we also sought to
demonstrate that this method could be used to prepare the C2-
symmetric diketopiperazines found in natural products such as
4 and 27. Global deprotection of diene 7 was eﬀected by
treatment with excess TBAF, and hydrolysis with aq. LiOH
aﬀorded amino acid 24 (Scheme 3). Dimerization using peptide
coupling reagent PyBroP furnished diketopiperazine 25, which
was epimerized to the thermodynamically favored anti-syn-anti
diastereomer 26 with cesium carbonate in MeOH. Diketopi-
perazine 26 has been utilized by Nicolaou and co-workers to
prepare both emethallicin E (4) and haemotocin (27) in three
additional steps; thus, the synthesis of 26 represents the formal
syntheses of these natural products.8a
In summary, we have developed an eﬃcient eight-step
strategy to synthesize cyclohexadienol 7, a key amino acid
building block that enabled the ﬁrst total synthesis of
(−)-acetylapoaranotin. An important feature of our strategy is
that the absolute stereochemistry of both the dihydrooxepine
and cyclohexadienol amino acid building blocks is set through
catalytic asymmetric (1,3)-dipolar cycloaddition reactions. We
have also demonstrated that 7 can be used to prepare a dimeric
cyclohexadienol-containing diketopiperazine, which represents
the formal syntheses of (−)-emethallicin E and (−)-haemoto-
cin. Intermediates in this synthetic route could potentially be
utilized to prepare other structurally related 6,5-bicycle-
containing ETP natural products, for example, (−)-epicorazine
A5j (4, Figure 1) and (+)-epicoccin A.20 Synthetic studies
directed toward realizing these goals are ongoing in our
laboratory.
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